{"TopicDetails": {"type": 0, "ccm2Id": 46015293, "cftId": 0, "identifier": "HORIZON-JU-GH-EDCTP3-2023-01-05", "title": "Strengthening ethics and regulatory capacity", "publicationDateLong": 1681430400000, "callIdentifier": "HORIZON-JU-GH-EDCTP3-2023-01", "callTitle": "HORIZON-JU-GH-EDCTP3-2023-01", "callccm2Id": 46015337, "allowPartnerSearch": true, "frameworkProgramme": {"id": 43108390, "abbreviation": "HORIZON", "description": "Horizon Europe Framework Programme (HORIZON)"}, "programmeDivision": [{"id": 43108557, "abbreviation": "HORIZON.2.1", "description": "Health"}, {"id": 43108541, "abbreviation": "HORIZON.2", "description": "Global Challenges and European Industrial Competitiveness"}], "topicMGAs": [], "tags": ["edctp3", "regulatory agency", "capacity building", "clinical research", "clinical trials", "global health", "edctp", "Africa", "sub-Saharan Africa", "regulatory sciences", "health", "capacity development", "infectious diseases", "ethics committee", "regulatory capacity", "regulatory agencies"], "keywords": ["Clinical trials", "Societal Engagement", "Regulatory affairs", "Africa", "Clinical research", "Social sciences and humanities", "Public health", "Infectious diseases", "International Cooperation", "Global health"], "flags": ["SocietalEngagement", "Africa", "SSH", "EC-WORLD"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "HORIZON-JU-CSA HORIZON JU Coordination and Support Actions", "typeOfMGA": [{"id": 43027846, "abbreviation": "HORIZON-AG", "description": "HORIZON Action Grant Budget-Based"}]}], "plannedOpeningDate": "10 May 2023", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["04 July 2023"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3484194": [{"action": "HORIZON-JU-GH-EDCTP3-2023-01-03 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "10 May 2023", "deadlineModel": "single-stage", "deadlineDates": ["04 July 2023"], "budgetYearMap": {"2023": 26000000}, "expectedGrants": 6, "minContribution": 4000000, "maxContribution": 4000000, "budgetTopicActionMap": {}}], "3484196": [{"action": "HORIZON-JU-GH-EDCTP3-2023-01-02 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "10 May 2023", "deadlineModel": "single-stage", "deadlineDates": ["04 July 2023"], "budgetYearMap": {"2023": 14000000}, "expectedGrants": 12, "minContribution": 200000, "maxContribution": 2500000, "budgetTopicActionMap": {}}], "3484198": [{"action": "HORIZON-JU-GH-EDCTP3-2023-01-04 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "10 May 2023", "deadlineModel": "single-stage", "deadlineDates": ["04 July 2023"], "budgetYearMap": {"2023": 11000000}, "expectedGrants": 4, "minContribution": 3000000, "maxContribution": 3000000, "budgetTopicActionMap": {}}], "3484200": [{"action": "HORIZON-JU-GH-EDCTP3-2023-01-05 - HORIZON-JU-CSA HORIZON JU Coordination and Support Actions", "plannedOpeningDate": "10 May 2023", "deadlineModel": "single-stage", "deadlineDates": ["04 July 2023"], "budgetYearMap": {"2023": 8000000}, "expectedGrants": 8, "minContribution": 1000000, "maxContribution": 1000000, "budgetTopicActionMap": {}}], "3484202": [{"action": "HORIZON-JU-GH-EDCTP3-2023-01-01 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "10 May 2023", "deadlineModel": "single-stage", "deadlineDates": ["04 July 2023"], "budgetYearMap": {"2023": 15300000}, "expectedGrants": 3, "minContribution": 5000000, "maxContribution": 5000000, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2023"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p>Projects funded under this Call for Proposals should contribute to the following outcomes:</p><ul level=\"0\"><li>Stronger functionality, recognition, and performance of National Ethics Committees (NECs) and National Regulatory Agencies (NRAs) working in sub-Saharan Africa (SSA);</li><li>Clinical trials authorised in these areas meet the appropriate standards;</li><li>Improved efficiency regarding the process of clinical trial protocol authorisation for the development of new or improved health technologies;</li><li>Improved efficiency of the NRAs concerning clinical trials oversight with alignment to continental initiatives of African Medicine Agency (AMA) and African Medicines Regulatory Harmonisation (AMRH);</li><li>Better equipped health research systems to integrate new or improved health technologies;</li><li>Sustainable health research strategies for both NECs and NRAs;</li><li>Adoption of standardised training of both ethics committees and regulatory boards available in SSA through EDCTP partners;</li><li>Generation of principles towards harmonised oversight for certification of clinical trial ethics and regulatory bodies in SSA countries;</li><li>Creation of sustainable links and collaboration between NECs and NRAs and other important structures, such as clinical trial registries, research integrity offices and data access committees;</li><li>Establishment of systematic reviews and data sharing in compliance with global requirements;</li><li>Implementation of digital technologies to facilitate ethical and/or regulatory review processes.</li> </ul>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>The aim of this call is to improve the functionality, recognition and performance of NECs and NRAs for carrying out clinical trials in SSA countries<strong>. </strong></p><p>Despite ongoing efforts by different partners and agencies, ethics, and regulatory oversight in SSA countries requires prioritisation and ownership by these countries to ensure sustained strengthening with a long-term perspective. There is a need to better understand the challenges that these countries are facing. They include the varied levels of clinical trial activity, with no health research legislation in some of them; as well as the need of better quality control, certification and accreditation of ethics and regulatory bodies, adherence to common international standards and open data access. Coherent linkages between ethics and regulatory functions are needed, as well as linkages with clinical trial registration and more systematic research reviews. Furthermore, better systems and technologies, including more external expertise and digitalisation for processing research application review and handling of documentation and data, are required.</p><p>Several initiatives have already established capacity development tools and structures that add value to the capacity development efforts of ethics and regulatory agencies in SSA<sup>[1]</sup> and should be taken into consideration.</p><p>The projects funded under this call will support the SSA countries to establish and/or develop own robust capacities for ethics review and national medicines regulatory systems. This also includes support towards national and international collaboration in compliance with established international standards. This scheme targets proposals with active involvement of NECs and/or NRAs from SSA countries, and in particular with those countries with the highest infectious disease burden.</p><p>Proposals should address several of the following activities:</p><ul level=\"0\"><li>Improvement of the efficiency of the functioning of NECs and NRAs through the introduction of innovative systems, reliance practices and/or technologies that would facilitate the various functions of these bodies with better quality outputs and improved timelines;</li><li>Development of national health research legislation;</li><li>Promotion of quality control systems and processes for NECs and NRAs, as well as certification and accreditation of the various bodies, as well as adherence to international standards;</li><li>Promotion of international cooperation in ethics and regulatory activities through transfer of promising and successful innovative systems and/or technologies from other regions in Africa or other continents, fostering national and regional collaboration among these bodies;</li><li>Creation of linkages between ethics and regulatory functions with other important structures, such as clinical trial registries, whilst simultaneously enforcing the sharing of data in compliance with global requirements;</li><li>Promotion of the adoption and update of AVAREF, WHO and other international standards and best practices, by countries, groups of countries, or regional harmonisation initiatives;</li><li>Support already established training centres to provide both innovative training, and mentorship to NECs and NRAs.</li><li>Development or scale-up of innovative systems and technologies that support ethics and regulatory functions, training, networking and promotion of good practices and evidence-based adoption of accreditation models from relevant internationally endorsed/peer-reviewed documented sources.</li> </ul><p>Proposals should clearly indicate the mismatch between the country disease burden, research activity and level of ethical review and regulatory oversight that justify the need for support in these areas.</p><p>Linkages of the proposal to relevant on-going initiatives and regional bodies is encouraged and should be demonstrated.<sup>[2]</sup> Plans to foster bi-lateral links between the European Medicines Agency (EMA) and the national ethics and regulatory authorities in the SSA countries of the participants are encouraged.</p><p>Each proposal should have at least two new technical staff members recruited to the NEC/NRA team to be trained and integrated in the new functions proposed in the action. The new staff members should have a well-defined function and objectives in the participating NEC and NRA with a systems approach. The new staff members should stay in the team for at least two years and participate in relevant networking and international events.</p><p>Particular attention should also be paid in the proposal for ensuring complementarity and coherence with other activities supported by the European Union and EU Member States in the countries involved. This concerns for example the EDCTP Regional Networks of Excellence<sup>[3]</sup> and the Team Europe initiative on Manufacturing and Access to Vaccines, Medicines, and Health Technologies (MAV+) in Africa<sup>[4]</sup> or other health Team Europe initiatives<sup>[5]</sup> of the Global Gateway investment package.</p><p>To strengthen the clinical research capacity in the SSA regions with the highest disease burden, the quality of the transfer of knowledge should be taken particularly into account when evaluating the criterion \u2018impact\u2019<em>.</em></p><p>Proposals should provide details on the steps to be taken to ensure gender balance and contribute to have representation from French speaking and Portuguese speaking SSA countries in the project team.</p><p><sup>[1]</sup>WHO AFRO, through AVAREF, has established a training course for ethics committees in both English and French. AUDA-NEPAD has established Regional Centres of Regulatory Excellence (RCOREs) designated with regulatory science expertise and training capabilities. Moreover, WHO has also developed standards for ranking maturity of regulatory boards as a measure to indicate advancement in capacity of these agencies.</p><p><sup>[2]</sup>These initiatives include: the African Medicines Agency (AMA), the Africa Vaccines Regulators Forum (AVAREF), the Regional Centres of Regulatory Excellence (RCORE) in Africa, the WHO-TDR-SIDCER initiative (Strategic Initiative for Developing Capacity in Ethical Review), the Pan African Clinical Trials Registry (PACTR), the African Medicines Regulatory Harmonisation (AMRH) and the Africa Centre for Disease Control and Prevention (ACDC) and WHO-AFRO.</p><p><sup>[3]</sup>EDCTP regional networks of excellence strengthen regional networking and provide platforms for research training and multicentre studies <a href=\"http://www.edctp.org/our-work/edctp-regional-networks-of-excellence/\">http://www.edctp.org/our-work/edctp-regional-networks-of-excellence/</a></p><p><sup>[4]</sup>The Team Europe initiative (TEI) on Manufacturing and Access to Vaccines, Medicines and Health Technologies (MAV+) <a href=\"http://ec.europa.eu/commission/presscorner/detail/en/ip_21_2594\">https://ec.europa.eu/commission/presscorner/detail/en/ip_21_2594</a> directly funds the European Medicines Agency (EMA), African Medicine Agency AUDA-NEPAD (AMA) and the World Health Organization (WHO).</p><p><sup>[5]</sup>Team Europe Initiative with Africa on sustainable health security using a One Health approach <a href=\"http://europa.eu/capacity4dev/tei-jp-tracker/tei/sustainable%C2%A0health-security-africa\">https://europa.eu/capacity4dev/tei-jp-tracker/tei/sustainable%C2%A0health-security-africa</a></p>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<p><u>Expected impacts of the calls under the 2023 work programme of the Global Health EDCTP3 JU</u></p><p>Activities funded under the 2023 calls for proposals should contribute to:</p><ul level=\"0\"><li>Achieve SDG3 \u2018Ensure healthy lives and promote well-being for all at all ages\u2019 in sub-Saharan African countries;</li><li>Enable the implementation of the short and medium term actions foreseen by the AU EU Innovation Agenda<sup>[1] </sup>(expected to be adopted in June 2023) in the area of Public Health</li><li>Provide evidence for informed health policies and guidelines within public health systems in sub-Saharan Africa and at international level;</li><li>Strengthen clinical research capability in sub-Saharan Africa to rapidly respond to emerging epidemics;</li><li>Enable a regulatory environment that can ensure effective development, delivery, and uptake of new or improved safe health technologies guaranteeing that trials in sub-Saharan African countries meet international standards;</li><li>Increase cost effectiveness of public investment through collaboration of funders of clinical trials in the area of infectious diseases in sub-Saharan Africa;</li><li>Strengthen health systems to ensure uptake of effective health technologies and innovations;</li><li>Enhance sustainable global scientific collaboration in health research and international cooperation across sub-Saharan Africa.</li><li>Improve opportunities for training of researchers and healthcare professionals in sub-Saharan Africa.</li> </ul><p><sup>[1]</sup>Working document of the AU EU Innovation Agenda available online at: <a href=\"http://research-and-innovation.ec.europa.eu/system/files/2022-02/final_au-eu_ia_14_february.pdf\">https://research-and-innovation.ec.europa.eu/system/files/2022-02/final_au-eu_ia_14_february.pdf</a></p>\n", "conditions": "<h1><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\" style=\"line-height: 115%;\">General conditions</span></b></span></span></span></h1>\r\n<p class=\"MsoNormal\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">1. Admissibility conditions: </span></b><span lang=\"EN-US\">described in </span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex A</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">and </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#10;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex E</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Horizon Europe Work Programme General Annexes</span></span></span></p>\n<p style=\"margin-left: 40px;\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\"> described in Part B of the Application Form available in the Submission System</span></span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">2. Eligible countries:&nbsp;</span></b></span></span></span></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">The conditions are described in General Annex B except for the specific conditions for GH EDCTP3 funding as regards&nbsp;<u>Entities eligible for funding</u>&nbsp;and&nbsp;<u>Consortium composition,</u>&nbsp;the specific issue of&nbsp;<u>legal entities from which countries can be the coordinator</u>&nbsp;and the obligation to designate a&nbsp;<u>scientific project leader</u>. Participation conditions related to Russia&rsquo;s illegal invasion of Ukraine are also set out below.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong><u>Replacing relevant sections in General Annex B to the Horizon Europe work programmes on Eligibility</u></strong></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><em><u>Entities eligible to participate</u></em></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">Given the illegal invasion of Ukraine by Russia and the involvement of Belarus, the currently context does not allow the implementation of the actions foreseen in this programme with legal entities established in Russia, Belarus, or in non-government-controlled territories of Ukraine. Therefore, such legal entities are not eligible to participate in any capacity. This criterion also applies in cases where the action involves financial support given by grant beneficiaries to third parties established in Russia, Belarus or in non-government-controlled territories of Ukraine (in accordance with Article 204 of the Financial Regulation No 2018/1046).</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">To be eligible for funding, applicants must be established in one of the following countries:</p>\r\n<ul level=\"0\" style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">\r\n    <li>The Member States of the European Union, including their outermost regions: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden;</li>\r\n    <li>The Overseas Countries and Territories (OCTs) linked to the Member States: Aruba (NL), Bonaire (NL), Cura&ccedil;&atilde;o (NL), French Polynesia (FR), French Southern and Antarctic Territories (FR), Greenland (DK), New Caledonia (FR), Saba (NL), Saint Barth&eacute;lemy (FR), Sint Eustatius (NL), Sint Maarten (NL), St. Pierre and Miquelon (FR), Wallis and Futuna Islands (FR);</li>\r\n    <li>Countries associated to Horizon Europe<sup>[1]</sup>; Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Kosovo<sup>[2]</sup>, Moldova, Montenegro, North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine. Considering the Union&rsquo;s interest to retain, in principle, relations with the countries associated to Horizon 2020, most third countries associated to Horizon 2020 are expected to be associated to Horizon Europe with an intention to secure uninterrupted continuity between Horizon 2020 and Horizon Europe. In addition, other third countries can also become associated to Horizon Europe during the programme. For the purposes of the eligibility conditions, applicants established in Horizon 2020 Associated Countries or in other third countries negotiating association to Horizon Europe will be treated as entities established in an Associated Country, if the Horizon Europe association agreement with the third country concerned applies at the time of signature of the grant agreement<sup>[3]</sup>;</li>\r\n    <li>The following low- and middle-income countries which are constituent states of the EDCTP Association<sup>[4]</sup>: Burkina Faso, Cameroon, Congo, C&ocirc;te d&rsquo;Ivoire, Democratic Republic of the Congo, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Kenya, Liberia, Malawi, Mali, Mozambique, Niger, Nigeria, Rwanda, Senegal, South Africa, Tanzania, Uganda, Zambia, Zimbabwe.</li>\r\n</ul>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">Legal entities which are established in countries not listed above will be eligible for funding if provided for in the specific call conditions, or if their participation is considered essential for implementing the action by the granting authority.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong><em><u>Consortium composition</u></em></strong></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">Unless otherwise provided for in the specific call conditions, for all actions, due to the policy objectives of the GH EDCTP3 JU, legal entities forming a consortium are eligible to participate in actions under the programme provided that the consortium includes:</p>\r\n<ul level=\"0\" style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">\r\n    <li>At least three legal entities established in different countries, where legal entities are eligible to receive funding;</li>\r\n    <li>At least one independent legal entity established in a Member State or an associated country; and</li>\r\n    <li>At least one independent legal entity established in a sub-Saharan African (SSA) country that is a member of the EDCTP Association.</li>\r\n</ul>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><em>Specific cases:</em></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong>Affiliated entities</strong>&nbsp;&ndash; Affiliated entities are eligible for funding if they are established in one of the countries listed above.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong>International organisations</strong>&nbsp;&ndash; International European research organisations are eligible to receive funding. Other international organisations are not eligible to receive funding unless their participation is considered essential for implementing the action by the granting authority. International organisations with headquarters in a Member State or associated country are eligible to receive funding when provided for in the specific call conditions.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong><em><u>Specific rules on which legal entities can be the coordinator of an indirect action</u></em></strong></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">According to article 110 of the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe<sup>[5]</sup>, where entities established in a third country without an agreement to protect the financial interests of the Union participate with funding in an indirect action, the financial coordinator of the indirect action shall be established in a Member State or associated country. Of the SSA countries members of the EDCTP Association, only South Africa concluded such an agreement.<sup>[6]</sup></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong><em><u>Scientific project leader</u></em></strong></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">If the coordinator is not established in a country in sub-Saharan Africa (SSA), the designation of a scientific project leader established in a SSA country member of the EDCTP Association with the roles as described below is mandatory. A work package on &lsquo;scientific project leadership&rsquo; must be included in the proposals and budget needs to be provided for this activity.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">The scientific project leader oversees the project scientific governance and leadership. For this purpose, proposals must include a work package where the details of scientific project leadership are laid down. The scientific project leader should indicatively perform the following tasks:</p>\r\n<ul level=\"0\" style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">\r\n    <li>During the call for proposals and selection process, coordinate meetings on and drafting of the full project proposal;</li>\r\n    <li>Work with the coordinator and other beneficiaries on the drafting and negotiation of the consortium agreement and other legal agreements among the beneficiaries;</li>\r\n    <li>Act as the key contact point for the GH EDCTP3 regarding all scientific action governance issues, steer and provide oversight in the development of the scientific actions, acting as the key contact point for the GH EDCTP3 JU for these matters including external communication, other than the ones entrusted directly to the coordinator as per the Model Grant Agreement;</li>\r\n    <li>Support and collaborate with the coordinator on its monitoring activities and the adoption of appropriate internal measures, to ensure that beneficiaries are fulfilling their obligations regarding budget, timeline, deliverables, and scientific quality;</li>\r\n    <li>Review the action&rsquo;s deliverables and reports before their submission by the coordinator;</li>\r\n    <li>Lead the work packages(s) related to the tasks of scientific project leadership.</li>\r\n</ul>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">Annex 1 to the grant agreement and the consortium agreement should address the relationship of the scientific project leader with the coordinator regarding their respective tasks, for example sharing of the information received from or sent to the GH EDCTP3 JU on all issues of interest for the proper scientific management of the action.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[1]</sup>The list is correct at the time of adoption of this work programme. Please see the Horizon Europe List of Participating Countries on the Funding &amp; Tenders Portal for up-to-date information on the current list and on the position for Associated Countries.&nbsp;<a href=\"http://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf\" style=\"color: rgb(51, 51, 51);\">https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[2]</sup>This designation is without prejudice to positions on status and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[3]</sup>Association of New Zealand is expected to take effect during 2023.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[4]</sup>The list is correct at the time of adoption of this work programme. For an update, please check the EDCTP Association website&nbsp;<a href=\"http://www.edctp.org/\" style=\"color: rgb(51, 51, 51);\">www.edctp.org</a>.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[5]</sup>Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014.&nbsp;<em>OJ L 427, 30.11.2021, p. 17&ndash;119; https://eur-lex.europa.eu/eli/reg/2021/2085</em></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[6]</sup><a href=\"http://research-and-innovation.ec.europa.eu/strategy/strategy-2020-2024/europe-world/international-cooperation/south-africa_en\" style=\"color: rgb(51, 51, 51);\">https://research-and-innovation.ec.europa.eu/strategy/strategy-2020-2024/europe-world/international-cooperation/south-africa_en</a></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">3. Other eligibility conditions:</span></b><span lang=\"EN-US\"> described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#10;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex B</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> <span lang=\"EN-US\">of the Work Programme General Annexes</span></span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b>4. Financial and operational capacity and exclusion: </b>described in </span></span></span><span style=\"mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex C</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> of the Work Programme General Annexes</span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"FR-BE\">5.&nbsp;Evaluation and award:</span></b></span></span></span></p>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Award criteria, scoring and      thresholds</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      D</span></span></a></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">of      the Work Programme General Annexes</span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<p><strong><u>Replacing relevant section in General Annex D to the Horizon Europe work programmes</u></strong></p><p><strong><em><u>Scores and weighting</u></em></strong></p><p>Evaluation scores will be awarded for the criteria, and not for the different aspects listed in the table. For full applications, each criterion will be scored out of 5. The threshold for individual criteria 1 (Excellence) and 2 (Impact) will be 4 and for criteria 3 (Quality and efficiency of the implementation) will be 3. The overall threshold, applying to the sum of the three individual scores, will be 12.</p><p>Proposals that pass the individual threshold and the overall threshold will be considered for funding, within the limits of the available call budget. Other proposals will be rejected.</p>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Submission and evaluation      processes</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of      the Work Programme General Annexes and the </span></span></span></span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Online      Manual</span></span></a><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Indicative timeline for      evaluation and grant agreement: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes</span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">6. Legal and financial set-up of the grants: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#10;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex G</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes</span></span></span></span></p>\r\n<p>&nbsp;</p>\n<h1><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\" style=\"line-height: 115%;\">Specific conditions</span></b></span></span><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:&#10;11.0pt;line-height:115%;mso-ansi-language:EN-US\"><o:p></o:p></span></b></h1>\r\n<p class=\"MsoNormal\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">7. Specific conditions: </span></b><span lang=\"EN-US\">described in the specific topic of the Work Programme</span></span></span></span></p>\r\n<p class=\"MsoNormal\"><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\"><b>Scientific Project Leader</b></span></font></p>\r\n<p class=\"MsoNormal\"><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\">For all projects under this topic, if the coordinator is not established in a country in sub-Saharan Africa (SSA), the designation of a scientific project leader established in a SSA country member of the EDCTP Association with the roles as described in the introduction is mandatory. A work package on &lsquo;scientific project leadership&rsquo; must be included in the proposals and budget needs to be provided for this activity.</span></font><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\"><br />\r\n</span></font></p>\r\n<p class=\"MsoNormal\"><strong><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\">Grant Conditions - EC objection to transfer of ownership to a third party in a third country</span></font></strong></p>\r\n<p class=\"MsoNormal\"><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\">According to the Horizon Europe rules, and to protect Union interests, the right for the GH EDCTP3 to object to transfers of ownership of results or to grants of an exclusive licence regarding results should apply to participants. Therefore, the provisions set out in General Annex G to the Horizon Europe work programmes on the right to object apply generally. It should be noted that in accordance with the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe[1] and the Model Grant Agreement, the right to object applies also to participants that have not received funding from the JU and for the periods set therein.</span></font><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\"><br />\r\n</span></font></p>\r\n<p class=\"MsoNormal\"><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\">[1] Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014; OJ L 427, 30.11.2021, p. 17</span></font></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\"><o:p></o:p></span></p>\n<h1><span style=\"font-size: medium;\"><b><span lang=\"EN-US\" style=\"line-height: 115%;\"><span style=\"font-family: Arial;\">Documents</span></span></b></span><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:&#10;11.0pt;line-height:115%;mso-ansi-language:EN-US\"><o:p></o:p></span></b></h1>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span style=\"color: rgb(0, 0, 0);\"><b><span lang=\"EN-US\">Call documents:</span></b></span></span></span><b><span lang=\"EN-US\"><o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"font-family: Arial; font-size: small;\">Standard application form</span><span style=\"font-family: Arial; font-size: small; color: rgb(128, 128, 128);\"><span lang=\"EN-US\">&nbsp;&mdash;<i>&nbsp;call-specific application form is available in the Submission System</i></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/af_he-csa_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Standard application form (HE CSA)</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><span style=\"font-size: small;\"><span lang=\"EN-US\">Standard evaluation form</span></span><span style=\"font-size: small; color: rgb(128, 128, 128);\"><span lang=\"EN-US\">&nbsp;&mdash;<i>&nbsp;will be used with the necessary adaptations</i></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/ef/ef_he-csa_en.pdf\"><span style=\"font-size: small;\"><span lang=\"EN-US\">Standard evaluation form (HE CSA)</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\">&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><span style=\"font-size: small;\">MGA</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/agr-contr/general-mga_horizon-euratom_en.pdf\" style=\"font-size: small;\"><span style=\"font-size: small;\">HE <span lang=\"EN-US\">General MGA v1.0</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"color: rgb(64, 64, 64); font-size: small;\">Call-specific instructions</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/information-on-financial-support-to-third-parties_he_en.docx\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Information on financial support to third parties (HE)</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/information-on-clinical-studies_he_en.docx\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Information on clinical studies (HE)</span></span></a></span></p>\n<h2><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Additional documents:</span></b></span></span></span></h2>\r\n<h2 style=\"margin-top:0cm\"><b><span lang=\"EN-US\"><o:p></o:p></span></b></h2>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><a href=\"https://research-and-innovation.ec.europa.eu/document/download/43297f62-5b31-4375-a54a-a5d3f1b52f44_en?filename=edctp_work_programme_2023.pdf\" target=\"_blank\">Work Programme 2023</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><a href=\"https://research-and-innovation.ec.europa.eu/document/download/096afd45-ee04-4aff-9325-138ae37eaa39_en?filename=edctp_wp2023-annex1_calls_for_proposals.pdf\" target=\"_blank\">Annex 1 - Calls for proposals</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><a href=\"https://research-and-innovation.ec.europa.eu/document/download/deb9e2bb-a8ab-48dd-b026-fc0fd4f6626b_en?filename=edctp_wp2023_annex_2_ikaa_plan.pdf\" target=\"_blank\">Annex 2 - In-kind contributions (IKAA plan)</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-1-general-introduction_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 1. General Introduction</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-4-health_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 4. Health</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 13. General Annexes</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Programme Guide</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0695\" target=\"_blank\" style=\"font-family: Arial;\"><span style=\"font-size: small;\">HE Framework Programme and Rules for Participation Regulation 2021/695</span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021D0764\" target=\"_blank\"><span style=\"font-size: small;\">HE Specific Programme Decision 2021/764</span></a></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Financial Regulation</span></span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/rules-lev-lear-fca_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/aga_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Grants AGA </span>&mdash; Annotated Model Grant Agreement</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">Funding &amp; Tenders Portal Online Manual</span></span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/tc_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Funding &amp; Tenders Portal Terms and Conditions</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/privacy-statement_en.pdf\" style=\"font-size: 11pt; font-family: Arial;\"><span style=\"font-size: small;\">Funding &amp; Tenders Portal Privacy Statement</span></a></p>", "supportInfo": "<p><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;font-weight:normal;mso-bidi-font-weight:bold\"><b><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\" target=\"_blank\">Online Manual</a>&nbsp;</b></span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">is your guide on the procedures from proposal submission to managing your grant.<o:p></o:p></span></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Horizon Europe Programme Guide</span></b></a><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;</span></strong><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif; font-weight: normal;\">contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;type=undefined;categories=;programme=H2020;actions=;keyword=\" target=\"_blank\">Funding &amp; Tenders Portal FAQ</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service_en\" target=\"_blank\">Research Enquiry Service</a></span>&nbsp;</b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</span></p>\r\n<p><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp\" target=\"_blank\">National Contact Points (NCPs)</a>&nbsp;</span></b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (&lsquo;third-countries&rsquo;).<b><o:p></o:p></b></span></p>\r\n<p><a href=\"https://een.ec.europa.eu/\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Enterprise Europe Network</span></b></a><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;color:#003366\">&nbsp;</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\" target=\"_blank\">IT Helpdesk</a></span></b>&nbsp;</span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash;&nbsp;contact the Funding &amp; Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://www.iprhelpdesk.eu/\" target=\"_blank\">European IPR Helpdesk</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;assists you on intellectual property issues.<br />\r\n<br />\r\n</span><b><a href=\"mailto:research@cencenelec.eu\" target=\"_blank\">CEN-CENELEC Research Helpdesk</a> and <a href=\"https://www.etsi.org/research/helpdesk\" target=\"_blank\">ETSI Research Helpdesk</a></b>&nbsp;<span style=\"font-family: Arial, sans-serif;\">&ndash;&nbsp;</span>the European Standards Organisations&nbsp;advise you how to tackle standardisation in your project proposal.&nbsp;&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-left:36.0pt\"><o:p></o:p></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://euraxess.ec.europa.eu/sites/default/files/am509774cee_en_e4.pdf\" target=\"_blank\">The European Charter for Researchers and the Code of Conduct for their recruitment</a></span></b></span><span style=\"font-size:&#10;9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366\"> </span><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366;font-weight:&#10;normal;mso-bidi-font-weight:bold\">&ndash; consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.</span></strong><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></b></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search\" target=\"_blank\">Partner Search Services</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;help you find a partner organisation for your proposal.<o:p></o:p></span></p>\r\n<p>&nbsp;</p>", "sepTemplate": "<p>To access the Electronic Submission Service, please click on the submission-button next to the <strong>type of action</strong> and the <strong>type of model grant agreement</strong> that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"additionalInfo": "<p>&nbsp;<span style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\">With the 2023 work programme we extend the range of topics addressed under the GH EDCTP3 JU, building on the activities launched in 2022. The work programme this year puts particular emphasis on capacity building and training. A topic calling for training networks is included (HORIZON-JU-GH-EDCTP3-2023-01-01). Also, for the other topics in the work programme, where relevant, support of African scientists through degree training in clinical research and/or hands on training during implementation of research projects should be provided to assist them in advancing their scientific careers. These scientists should be selected keeping gender balance in mind.</span></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\">In the context of this work programme, a clinical study covers clinical studies/trials/investigations/ cohorts and is defined as any systematic prospective or retrospective collection and analysis of health data obtained from individual patients or healthy persons to address scientific questions related to the understanding, prevention, diagnosis, monitoring or treatment of a disease, mental illness, or physical condition. It includes but it is not limited to clinical studies as defined by Regulation 536/2014 (on medicinal products), clinical investigation and clinical evaluation as defined by Regulation 2017/745 (on medical devices), performance study and performance evaluation as defined by Regulation 2017/746 (on in vitro diagnostic medical devices).</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\">From 31 January 2023, all initial clinical trial applications in the European Union (EU) must be submitted via the Clinical Trials Information System (CTIS). CTIS is now the single-entry point for sponsors and regulators of clinical trials for the submission and assessment of clinical trial data. This follows a one-year transition, during which sponsors could choose whether to apply for a new clinical trial in the EU/EEA in line with the Clinical Trials Directive or under the new Clinical Trials Regulation (CTR), which entered into application on 31 January 2022.<sup>[2]</sup></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\">In the context of this work programme, FAIR data are data which meet principles of findability, accessibility, interoperability, and reusability. Data can include exploitation of information and data from European data infrastructures and programmes such as Copernicus, European Space Agency, and the GEO initiative. For further details, see the FAIR principles website<sup>[3]</sup>, the FAIR cookbook<sup>[4]</sup>&nbsp;and the guides for researchers on how to make your data FAIR.<sup>[5]</sup></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[1]</sup><a href=\"http://commission.europa.eu/system/files/2022-01/ec_rtd_edctp3-sria-2022.pdf\" style=\"color: rgb(51, 51, 51);\">https://commission.europa.eu/system/files/2022-01/ec_rtd_edctp3-sria-2022.pdf</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[2]</sup><a href=\"http://www.ema.europa.eu/en/news/use-clinical-trials-information-system-becomes-mandatory-new-clinical-trial-applications-eu\" style=\"color: rgb(51, 51, 51);\">https://www.ema.europa.eu/en/news/use-clinical-trials-information-system-becomes-mandatory-new-clinical-trial-applications-eu</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[3]</sup><a href=\"http://www.go-fair.org/fair-principles/\" style=\"color: rgb(51, 51, 51);\">https://www.go-fair.org/fair-principles/</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[4]</sup><a href=\"http://faircookbook.elixir-europe.org/content/home.html\" style=\"color: rgb(51, 51, 51);\">https://faircookbook.elixir-europe.org/content/home.html</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[5]</sup><a href=\"http://www.openaire.eu/how-to-make-your-data-fair\" style=\"color: rgb(51, 51, 51);\">https://www.openaire.eu/how-to-make-your-data-fair</a></p>", "latestInfos": [{"approvalDate": "Nov 14, 2023 3:12:10 PM", "lastChangeDate": "Nov 14, 2023 3:12:10 PM", "content": "<p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\">EVALUATION RESULTS <o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Call Identifier: HORIZON-JU-GH-EDCTP3-2023-01<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Published: 14/04/2023<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Deadline: 04/07/2023<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Available budget: 74.3 million EUR<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\"><o:p>&nbsp;</o:p></span></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\">The results of the evaluation are as follows<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number proposals submitted: 99<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number ineligible proposals: 8<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number of above-threshold: 46<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Total budget requested for above-threshold proposals: 152.8 million EUR<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number of Main list: 25<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number of Reserve list: 8<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number of rejected proposals due to budgetary resources: 13<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">Number of proposal upgraded from Reserve list to Main list: 2<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\"><o:p>&nbsp;</o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">We recently informed the applicants about the evaluation results for their proposals.<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\">For questions, please contact us at <a href=\"mailto:EC-GLOBAL-HEALTH-EDCTP3@ec.europa.eu\">EC-GLOBAL-HEALTH-EDCTP3@ec.europa.eu</a></span></p>\r\n</p>"}, {"approvalDate": "Jul 11, 2023 9:56:24 AM", "lastChangeDate": "Jul 11, 2023 9:56:24 AM", "content": "<p><font color=\"#333333\"><span style=\"font-size: 14px;\">Call Single Stage HORIZON-JU-GH-EDCTP3-2023-01 closed on July 4th, 2023.&nbsp;</span></font></p>\r\n<p class=\"MsoNormal\" style=\"background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><font color=\"#333333\"><span style=\"font-size: 14px;\">A total of 99 proposals were submitted.&nbsp;</span></font></p>\r\n<p><font color=\"#333333\"><span style=\"font-size: 14px;\">The breakdown per topic is:</span></font></p>\r\n<ul>\r\n    <li><font color=\"#333333\"><span style=\"font-size: 14px;\">HORIZON-JU-GH-EDCTP3-2023-01-01: 25 proposals&nbsp;</span></font></li>\r\n    <li><font color=\"#333333\"><span style=\"font-size: 14px;\">HORIZON-JU-GH-EDCTP3-2023-01-02: 18 proposals</span></font></li>\r\n    <li><font color=\"#333333\"><span style=\"font-size: 14px;\">HORIZON-JU-GH-EDCTP3-2023-01-03: 28 proposals</span></font></li>\r\n    <li><font color=\"#333333\"><span style=\"font-size: 14px;\">HORIZON-JU-GH-EDCTP3-2023-01-04: 10 proposals</span></font></li>\r\n    <li><font color=\"#333333\"><span style=\"font-size: 14px;\">HORIZON-JU-GH-EDCTP3-2023-01-05: 18 proposals</span></font></li>\r\n</ul>\r\n<p class=\"MsoNormal\" style=\"background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><font color=\"#333333\"><span style=\"font-size: 14px;\">Evaluation results are expected to be communicated on Friday 24th October 2023 at the earliest.</span></font></p>"}, {"approvalDate": "Jun 28, 2023 10:38:52 AM", "lastChangeDate": "Jun 28, 2023 10:38:52 AM", "content": "<p>The call deadline has been postponed to 04/07/2023</p>"}, {"approvalDate": "Jun 28, 2023 10:27:04 AM", "lastChangeDate": "Jun 28, 2023 10:27:04 AM", "content": "The submission session is now available for: HORIZON-JU-GH-EDCTP3-2023-01-03(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2023-01-02(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2023-01-05(HORIZON-JU-CSA), HORIZON-JU-GH-EDCTP3-2023-01-01(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2023-01-04(HORIZON-JU-RIA)"}, {"approvalDate": "May 10, 2023 12:00:01 AM", "lastChangeDate": "May 10, 2023 12:00:01 AM", "content": "The submission session is now available for: HORIZON-JU-GH-EDCTP3-2023-01-03(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2023-01-02(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2023-01-05(HORIZON-JU-CSA), HORIZON-JU-GH-EDCTP3-2023-01-01(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2023-01-04(HORIZON-JU-RIA)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}